CRISPR Therapeutics (CRSP +1.12%) has underperformed the broader market over the past five years, primarily due to challenging economic conditions and limited revenue from its only approved drug. However, the biotech firm’s promising pipeline, particularly in gene-editing therapies for cardiovascular disease, could redefine treatment paradigms and drive long-term growth. Notably, its candidate CTX310 targets the ANGPTL3 gene to manage high LDL cholesterol and triglyceride levels, potentially offering a one-time treatment for high-risk patients.
The implications for the financial markets are significant. With an estimated 40 million Americans affected by high LDL and triglyceride levels, even a small addressable market could yield substantial returns if CTX310 and other pipeline candidates succeed. CRISPR’s focus on high unmet needs positions it strategically in the biotech sector, which is increasingly attracting investor interest despite its current unprofitability.
Investors willing to embrace risk may find CRISPR Therapeutics an intriguing opportunity, particularly as it navigates the complexities of clinical trials and regulatory approvals. However, caution is advised for those averse to volatility, given the potential for setbacks.
Source: fool.com